1. Academic Validation
  2. Variants in DOCK3 cause developmental delay and hypotonia

Variants in DOCK3 cause developmental delay and hypotonia

  • Eur J Hum Genet. 2019 Aug;27(8):1225-1234. doi: 10.1038/s41431-019-0397-2.
Kimberly Wiltrout 1 Alejandro Ferrer 2 Ingrid van de Laar 3 Kazuhiko Namekata 4 Takayuki Harada 4 Eric W Klee 2 Michael T Zimmerman 5 Margot A Cousin 2 Jennifer L Kempainen 6 Dusica Babovic-Vuksanovic 6 Marjon A van Slegtenhorst 3 Coranne D Aarts-Tesselaar 7 Rhonda E Schnur 8 Marisa Andrews 9 Marwan Shinawi 10
Affiliations

Affiliations

  • 1 Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
  • 2 Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
  • 3 Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • 4 Visual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • 5 Genomics Sciences & Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA.
  • 6 Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA.
  • 7 Department of Pediatrics, Amphia Hospital, Breda, The Netherlands.
  • 8 GeneDx, Gaithersburg, MD, USA.
  • 9 Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.
  • 10 Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA. [email protected].
Abstract

The DOCK3 gene encodes the Dedicator of cytokinesis 3 (DOCK3) protein, which belongs to the family of guanine nucleotide exchange factors and is expressed almost exclusively in the brain and spinal cord. We used whole exome sequencing (WES) to investigate the molecular cause of developmental delay and hypotonia in three unrelated probands. WES identified truncating and splice site variants in Patient 1 and compound heterozygous and homozygous missense variants in Patients 2 and 3, respectively. We studied the effect of the three missense variants in vitro by using site-directed mutagenesis and pull-down assay and show that the induction of Rac1 activation was significantly lower in DOCK3 mutant cells compared with wild type human DOCK3 (P < 0.05). We generated a protein model to further examine the effect of the two missense variants within or adjacent to the DHR-2 domain in DOCK3 and this model supports pathogenicity. Our results support a loss of function mechanism but the data on the patients with missense variants should be cautiously interpreted because of the variability of the phenotypes and limited number of cases. Prior studies have described DOCK3 bi-allelic loss of function variants in two families with ataxia, hypotonia, and developmental delay. Here, we report on three patients with DOCK3-related developmental delay, wide-based or uncoordinated gait, and hypotonia, further supporting DOCK3's role in a neurodevelopmental syndrome and expanding the spectrum of phenotypic and genotypic variability.

Figures